Malignant Carcinoid Tumors. An Analysis of 103 Patients with Regard to Tumor Localization, Hormone Production, and Survival
Overview
Affiliations
In a prospective study of 103 patients with carcinoid tumors consecutively referred for medical treatment, the most common sites of the primary tumors were the ileum (73%), bronchi (7%), and jejunum (4%). All patients had local metastases, and 96 (93%) also had liver metastases. The most common initial symptoms were diarrhea (32%), ileus (25%), and flush (23%). The overall frequency of diarrhea was 84% and of flush was 75%. Heart insufficiency caused by cardiac valve disease was seen in 33% of the patients. The carcinoid syndrome, including flush, diarrhea, and elevated urinary 5-hydroxyindole acetic acid (5-HIAA) concentrations, was manifested by 69 patients (67%), 64 of whom (93%) had carcinoid tumors of mid-gut origin. Elevated urinary 5-HIAA was found in 91 patients (88%), of which 89 displayed liver metastases. The plasma concentration of the tachykinin neuropeptide K (NPK) was elevated in 67 patients (66%), 63 of whom had tumors of the mid-gut region. Serum pancreatic polypeptide (PP) and human chorionic gonadotrophin alpha levels were elevated in 43% and 28% of the patients, respectively, and the highest levels were found in patients with metastatic bronchial carcinoid tumors. Thirty-nine of the 103 patients are now dead; 18 died of tumor progression, whereas 14 patients died of heart failure secondary to a carcinoid tricuspidal valve insufficiency. The estimated median survival from the time of histologic diagnosis was 14 years, and from the time of carcinoid syndrome was 8 years.
Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.
Sanchez M, Rodriguez F, Covenas R Int J Mol Sci. 2023; 24(12).
PMID: 37373115 PMC: 10297964. DOI: 10.3390/ijms24129962.
Yan F, Zhou Q, Lin Y, Yu C, Chang H, Li Y J Int Med Res. 2021; 49(8):3000605211034666.
PMID: 34459278 PMC: 8408898. DOI: 10.1177/03000605211034666.
Katharina Ingenerf M, Karim H, Fink N, Ilhan H, Ricke J, Treitl K Acta Radiol. 2021; 63(7):877-888.
PMID: 34225464 PMC: 9194807. DOI: 10.1177/02841851211024004.
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.
Tran C, Sherman S, Howe J Ann Surg Oncol. 2021; 28(5):2741-2751.
PMID: 33452604 PMC: 8604156. DOI: 10.1245/s10434-020-09566-4.
Kim J, Zimmerman M, Hong J J Gastrointest Oncol. 2020; 11(3):601-608.
PMID: 32655939 PMC: 7340808. DOI: 10.21037/jgo.2019.11.03.